Edition:
United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

23.60USD
21 Sep 2017
Change (% chg)

$-0.30 (-1.26%)
Prev Close
$23.90
Open
$23.95
Day's High
$24.10
Day's Low
$23.40
Volume
394,105
Avg. Vol
866,895
52-wk High
$33.00
52-wk Low
$13.60

Greene, Barry 

Mr. Barry E. Greene is an Independent Director of Acorda Therapeutics, Inc. Mr. Greene currently serves as President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc. Mr. Greene joined Alnylam in September 2003, bringing over 15 years of experience in the healthcare industry and in consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of VELCADE (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene’s past experiences included being Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck); Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and partner of Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice. He currently serves as a member of the board of directors of Karyopharm Therapeutics Inc. Mr. Greene previously was a member of the boards of directors of Regulus Therapeutics, LLC and Intercept Pharmaceuticals, Inc. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and serves as a Senior Scholar at Duke University, Fuqua School of Business.

Basic Compensation

Total Annual Compensation, USD 72,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 178,766
Fiscal Year Total, USD 250,766

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

3,433,220

Richard Batycky

--

David Lawrence

1,360,800

Andrew Blight

1,484,560

Jane Wasman

1,986,540

Burkhard Blank

3,521,550
As Of  30 Dec 2016